Gilead Sciences shows strong Q1 execution, pipeline momentum, and margin upside, led by HIV and PrEP launches. See why GILD ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. Goldman Sachs analyst ...

The health crisis has spilled into South Africa’s universities and research hubs. Institutions that once hosted major NIH- ...

Decreasing CD4 and lymphocyte counts in some participants receiving an oral combination therapy led to holds in the study.

Gilead’s HIV treatment trials involving an investigational integrase strand inhibitor (GS-1720) and an investigational capsid inhibitor (GS-4182) have been put on clinical hold by the Food and Drug ...

RayzeBio, the radiopharmaceutical unit of Bristol Myers Squibb , licensed an experimental drug and diagnostic agent for ...

Insmed shares rocketed on results for a pulmonary arterial hypertension drug that exceeded Wall Street expectations.

GILD slides 2.6% after FDA halts trials for HIV candidates, GS-1720 and GS-4182, over safety concerns in patients.

Trump administration officials are expected to release more details on their plan to lower prescription drug prices in the ...

With U.S. cuts to programs putting millions at risk, Canada needs to provide leadership to help prevent a resurgence of HIV: ...

Gilead Sciences has paused five clinical trials of its investigational HIV drugs GS-1720 and GS-4182 after the American medicines regulator raised safety concerns. The once-weekly oral regimen was ...